<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489201</url>
  </required_header>
  <id_info>
    <org_study_id>ZGDE1B</org_study_id>
    <nct_id>NCT02489201</nct_id>
  </id_info>
  <brief_title>A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer</brief_title>
  <official_title>A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, one-center, noncomparative, two-stages phase 1B trial assessed the tyrosine&#xD;
      kinase inhibitor donafenib tosylate tablets(400 mg/d,200mg bid) in patients with advanced,&#xD;
      inoperable oesophageal cancer progressing after chemotherapy .&#xD;
&#xD;
      The primary endpoint is the safety.The secondary endpoints are tumor response and&#xD;
      progression-free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, noncomparative, two-part phase 1B trial recruited patients with advanced,&#xD;
      inoperable oesophageal cancer. The primary objectives were to assess the safety for donafenib&#xD;
      tosylate tablets .The secondary objectives were to estimate tumor response, progression-free&#xD;
      survival, duration of response, and disease control rate (response plus stable disease); to&#xD;
      evaluate changes in quality of life(QoL); This study is 2-stages designing. The investigators&#xD;
      plan to enroll 19 patients in the first stage study. The investigators will start the&#xD;
      secondary stage study if the disease control rate &gt;=8/19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>54 weeks</time_frame>
    <description>percentage of any adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>54 weeks</time_frame>
    <description>Tumor evaluation by investigators according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>54 weeks</time_frame>
    <description>PFS was defined as the time from date of randomization to disease progression radiological or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>donafenib tosilate tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donafenib tosilate tablets</intervention_name>
    <description>200mg,bid</description>
    <arm_group_label>donafenib tosilate tablets</arm_group_label>
    <other_name>CM4307</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients provided written, informed consent.&#xD;
&#xD;
          -  Have histologically confirmed advanced oesophageal squamous-cell carcinoma, or type&#xD;
             I/II Siewert junctional tumours.&#xD;
&#xD;
          -  Have received up to two previous chemotherapy regimens( Platinum containing regimens &amp;&#xD;
             Paclitaxel / docetaxel containing regimens).&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group Performance status of 0-1.&#xD;
&#xD;
          -  Have ability to swallow tablets.&#xD;
&#xD;
          -  no contraindications to sorafenib or donafenib.&#xD;
&#xD;
          -  Have either measurable or evaluable lesion on CT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with brain metastases.&#xD;
&#xD;
          -  Patients receiving cytotoxic chemotherapy, immunotherapy or hormonal therapy,&#xD;
             radiotherapy to site of measurable or evaluable disease within the previous 4 weeks.&#xD;
&#xD;
          -  Patients had evidence of clinically active interstitial lung disease or abnormal blood&#xD;
             results by predefined criteria (serum bilirubin &gt;1.5 times upper limit of reference&#xD;
             range, aspartate or alanine aminotransferase&gt;2.5 times the upper limit of normal if no&#xD;
             demonstrable liver disease) .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianming Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Military Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Affiliated Cancer Center of Academy of Military Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>donafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

